CareDx Inc (NASDAQ:CDNA) insider Sasha King sold 2,500 shares of the firm’s stock in a transaction on Friday, February 15th. The stock was sold at an average price of $25.00, for a total value of $62,500.00. Following the completion of the transaction, the insider now owns 76,387 shares in the company, valued at approximately $1,909,675. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of NASDAQ CDNA opened at $26.87 on Thursday. The company has a current ratio of 2.65, a quick ratio of 2.36 and a debt-to-equity ratio of 0.30. CareDx Inc has a 52 week low of $5.07 and a 52 week high of $30.80. The firm has a market capitalization of $1.02 billion, a P/E ratio of -34.90 and a beta of 1.20.
A number of institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC grew its position in CareDx by 55.6% in the fourth quarter. Millennium Management LLC now owns 163,023 shares of the company’s stock valued at $4,098,000 after acquiring an additional 58,280 shares during the last quarter. Legal & General Group Plc grew its position in CareDx by 19.5% in the fourth quarter. Legal & General Group Plc now owns 6,129 shares of the company’s stock valued at $154,000 after acquiring an additional 998 shares during the last quarter. Crawford Lake Capital Management LLC acquired a new stake in shares of CareDx during the fourth quarter valued at about $3,146,000. Gotham Asset Management LLC acquired a new stake in shares of CareDx during the fourth quarter valued at about $462,000. Finally, Metropolitan Life Insurance Co. NY boosted its stake in shares of CareDx by 356.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 11,356 shares of the company’s stock valued at $285,000 after purchasing an additional 8,869 shares in the last quarter. Hedge funds and other institutional investors own 79.20% of the company’s stock.
A number of research analysts recently commented on CDNA shares. BidaskClub cut CareDx from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 15th. HC Wainwright restated a “hold” rating and issued a $27.00 price target on shares of CareDx in a research report on Friday, December 21st. Craig Hallum restated a “buy” rating and issued a $40.00 price target on shares of CareDx in a research report on Friday, November 9th. Zacks Investment Research cut CareDx from a “buy” rating to a “hold” rating in a research report on Tuesday, January 8th. Finally, Jefferies Financial Group started coverage on CareDx in a research report on Friday, February 15th. They issued a “buy” rating and a $35.00 price target on the stock. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and two have given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $33.50.
COPYRIGHT VIOLATION NOTICE: “Sasha King Sells 2,500 Shares of CareDx Inc (CDNA) Stock” was originally posted by Macon Daily and is the property of of Macon Daily. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://macondaily.com/2019/02/21/sasha-king-sells-2500-shares-of-caredx-inc-cdna-stock.html.
CareDx Company Profile
CareDx, Inc, a transplant diagnostics company, together with its subsidiaries, engages in the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients worldwide. It operates through two segments, Post-Transplant Diagnostics and Pre-Transplant Diagnostics.
Featured Article: How Does the Quiet Period Work?
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.